Conditions

Keywords

recurrent cutaneous T-cell non-Hodgkin lymphomastage I cutaneous T-cell non-Hodgkin lymphomastage II cutaneous T-cell non-Hodgkin lymphomastage III cutaneous T-cell non-Hodgkin lymphomastage IV cutaneous T-cell non-Hodgkin lymphomarecurrent mycosis fungoides/Sezary syndromestage I mycosis fungoides/Sezary syndromestage II mycosis fungoides/Sezary syndromestage III mycosis fungoides/Sezary syndromestage IV mycosis fungoides/Sezary syndrome

Interventions

forodesine hydrochlorideDrug

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

DISEASE CHARACTERISTICS: * Histologically confirmed cutaneous T-cell lymphoma (CTCL) * Any stage except IA patch only * Previously treated according to 1 of the following: * Stage IA plaque, IB, or IIA: * At least 4 prior conventional and/or experimental regimens (topical or systemic, including psoralen-ultraviolet light \[PUVA\] and systemic corticosteroids) * Stage IIB, III, or IV: * At least 1 prior systemic regimen (systemic corticosteroids and PUVA do not count as systemic regimens for this purpose) NOTE: Repeated use of the same regimen is considered one regimen * Measurable disease PATIENT CHARACTERISTICS: Age * 18 and over Performance status * ECOG 0-3 Life expectancy * At least 3 months Hematopoietic * Granulocyte count at least 2,000/mm\^3 * Platelet count at least 75,000/mm\^3 * Hemoglobin at least 10.0 g/dL Hepatic * Bilirubin no greater than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's syndrome) * ALT no greater than 2 times ULN * Alkaline phosphatase no greater than 2 times ULN * No hepatitis B or C Renal * Creatinine clearance at least 45 mL/min Other * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * HIV negative * Human T-cell leukemia virus type 1 (HTLV-1) negative * No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix * No other illness that would limit study participation * No active serious infection not controlled by antibiotics PRIOR CONCURRENT THERAPY: Biologic therapy * No concurrent anticancer antibody therapy * No concurrent anticancer immunotherapy * No concurrent anticancer gene therapy * No concurrent anticancer vaccine therapy * No concurrent anticancer angiogenesis inhibitors * No concurrent sargramostim (GM-CSF) * No concurrent filgrastim (G-CSF) during course 1 of therapy Chemotherapy * More than 21 days since prior chemotherapy unless fully recovered * No concurrent anticancer chemotherapy Endocrine therapy * See Disease Characteristics * More than 2 weeks since prior topical corticosteroids * No concurrent anticancer hormonal therapy Radiotherapy * More than 2 weeks since prior radiotherapy * No concurrent radiotherapy Surgery * Not specified Other * More than 2 weeks since prior antineoplastic therapy * More than 21 days since prior investigational agents unless fully recovered * No concurrent citrate-blood products within 30 minutes before or after study treatment * No concurrent anticancer matrix metalloprotease inhibitors * No other concurrent anti-CTCL therapy * No concurrent use of tanning beds * No other concurrent investigational agents

Sponsors & Collaborators

BioCryst Pharmaceuticals
Industrylead

Study Sites (3)

University of Alabama at Birmingham Comprehensive Cancer Center

Birmingham, Alabama, 35294-3300, United States

Duke Comprehensive Cancer Center

Durham, North Carolina, 27710, United States

University of Texas - MD Anderson Cancer Center

Houston, Texas, 77030-4009, United States

MeSH Terms

Conditions

LymphomaLymphoma, T-Cell, CutaneousMycosis FungoidesSezary Syndrome

Condition Hierarchy (Ancestors)

Neoplasms by Histologic TypeNeoplasmsLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesLymphoma, T-CellLymphoma, Non-Hodgkin

Study Officials

Alex Shalaurov, MD, PhD
Inveresk Research Group, Incorporated
STUDY CHAIR

BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Keywords

Interventions

Eligibility Criteria

Sponsors & Collaborators

Study Sites (3)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Study Design

Study Record Dates

Source record

Locations